Open access
Open access
Powered by Google Translator Translator

Diabetes

Guideline | Management of individuals with diabetes at high risk for hypoglycemia.

8 Dec, 2022 | 13:08h | UTC

Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline – The Journal of Clinical Endocrinology & Metabolism

News Release: New Endocrine Society Clinical Practice Guideline examines better ways to manage hypoglycemia in people with diabetes – Endocrine Society

 


Guideline | Psychological care of children, adolescents and young adults with diabetes.

6 Dec, 2022 | 13:53h | UTC

ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes – Pediatric Diabetes

 


Practical Guidance | Insulin pumps and hybrid close loop systems within hospital.

5 Dec, 2022 | 00:16h | UTC

Insulin Pumps and Hybrid Close Loop Systems Within Hospital: A Scoping Review and Practical Guidance From the Joint British Diabetes Societies for Inpatient Care – Journal of Diabetes Science and Technology

 


Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.

25 Nov, 2022 | 12:42h | UTC

GLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)

Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist

 


RCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM.

21 Nov, 2022 | 14:45h | UTC

RCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM. 

Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text) 

Commentary: Continuous Monitoring Outperforms Fingerstick Testing in Patients With T1D, High Glycated Hemoglobin – AJMC 

 

Commentary on Twitter 

 


Guideline | Management of hyperosmolar hyperglycemic state in adults.

15 Nov, 2022 | 13:03h | UTC

Management of Hyperosmolar Hyperglycaemic State (HHS) in Adults: An updated guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care Group – Diabetic Medicine

Related: Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients – The BMJ

 


M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.

11 Nov, 2022 | 14:04h | UTC

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials – The Lancet

Commentaries:

Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD

Related: RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

 

Commentary on Twitter

Under a Creative Commons Attribution (CC BY 4.0) License

 


M-A | Head-to-head trials comparing sulfonylureas and low hypoglycemic risk antidiabetic drugs.

11 Nov, 2022 | 13:38h | UTC

Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs – BMC Endocrine Disorders

 


RCT | Efficacy of a digital behavioral therapeutic application to improve glycemic control in adults with Type 2 DM.

7 Nov, 2022 | 12:33h | UTC

Randomized, Controlled Trial of a Digital Behavioral Therapeutic Application to Improve Glycemic Control in Adults With Type 2 Diabetes – Diabetes Care

Commentary: Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes – medwire News

 


Crossover RCT | Efficacy of low-dose Empagliflozin as an adjunct to hybrid closed-loop insulin therapy in adults with Type 1 DM.

7 Nov, 2022 | 12:24h | UTC

Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial – Diabetes Care (link to abstract – $ for full-text)

 


Study suggests a personalized frequency of urinary albumin screening may be best for patients with Type 1 Diabetes.

3 Nov, 2022 | 13:46h | UTC

Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes – Diabetes Care (link to abstract – $ for full-text)

News Release: NIH-funded study finds personalized kidney screening for people with type 1 diabetes could reduce costs, detect disease earlier – National Institutes of Health

 


Development, validation and clinical utility of a risk prediction model for adverse pregnancy outcomes in gestational diabetes.

3 Nov, 2022 | 13:45h | UTC

Development, validation and clinical utility of a risk prediction model for adverse pregnancy outcomes in women with gestational diabetes: The PeRSonal GDM model – eClinicalMedicine

 

Commentary on Twitter (thread – click for more)

 


M-A | Association of SGLT2 inhibitors with cardiovascular outcomes and safety events.

1 Nov, 2022 | 11:56h | UTC

Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials – Frontiers in Cardiovascular Medicine

 


M-A of RCT | Comparison of low carbohydrate vs. low fat diets in Type 2 DM.

31 Oct, 2022 | 13:55h | UTC

Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials – Nutrients

 


RCT | Effects of a low-carbohydrate dietary intervention on hemoglobin A1c.

31 Oct, 2022 | 13:54h | UTC

Effects of a Low-Carbohydrate Dietary Intervention on Hemoglobin A1c: A Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

News Release: At risk for diabetes? Cut the carbs, says new study – Tulane University

Commentaries:

Expert reaction to study looking at effects of a low-carbohydrate dietary intervention and improved glycaemia – Science Media Centre

Low-Carb Diet Promising for Lowering Blood Sugar in Prediabetes – TCTMD

 


Cohort Study | Risk factors of pancreatic cancer in patients with Type 2 DM.

31 Oct, 2022 | 13:47h | UTC

Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study – Journal of the Endocrine Society

 


M-A | Age, sex, race, BMI, and duration of type 2 DM differences in cardiovascular outcomes with glucose lowering drugs.

26 Oct, 2022 | 14:32h | UTC

Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis – eClinicalMedicine

Commentary: Meta-analysis may guide optimal type 2 diabetes glucose-lowering agent for MACE protection – medwire News

 


KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.

24 Oct, 2022 | 14:16h | UTC

KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease – Kidney International

See also: Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence – Kidney International

Related: ADA/KDIGO Consensus Report | Diabetes management in chronic kidney disease.

 


M-A | Safety of sotagliflozin in diabetes mellitus type 1 and type 2.

19 Oct, 2022 | 14:12h | UTC

The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials – Frontiers in Endocrinology

 


M-A | Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes.

19 Oct, 2022 | 14:11h | UTC

Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials – BMJ Open

 


Retrospective Cohort Study | Trends in the association between diabetes and cardiovascular events, 1994-2019.

18 Oct, 2022 | 12:58h | UTC

Trends in the Association Between Diabetes and Cardiovascular Events, 1994-2019 – JAMA (free for a limited period)

Related Study: Study shows that the leading causes of hospitalization of adults with diabetes are changing.

 


RCT | Two-year effects of Semaglutide in adults with overweight or obesity.

18 Oct, 2022 | 12:53h | UTC

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial – Nature Medicine

Commentary: STEP 5: Sustained semaglutide treatment maintains weight loss – medwire News

Related:

RCT: Effect of continued weekly subcutaneous Semaglutide vs. placebo on weight loss maintenance in adults with overweight or obesity

RCT: High dose once a week Semaglutide (2.4 mg) in adults with overweight or obesity, and type 2 diabetes

RCT: Effect of high-dose subcutaneous Semaglutide vs. placebo in adults with overweight or obesity

RCT: Once-weekly, high-dose semaglutide is effective for improving overweight or obesity among non-diabetic adults

 

Commentary on Twitter

 


Cohort Study | Duration of diabetes and use of insulin are the most important predictors of diabetic retinopathy.

13 Oct, 2022 | 13:44h | UTC

Presence and development of diabetic retinopathy in 153 238 patients with type 2 diabetes in the Danish Registry of Diabetic Retinopathy – Acta Ophthalmologica

Commentary: Insulin Use May Predict the Development of Diabetic Retinopathy – HCP Live

 


Cohort Study | Effect of diabetes on morbidity and mortality in patients with acromegaly.

13 Oct, 2022 | 13:37h | UTC

Effect of Diabetes on Morbidity and Mortality in Patients With Acromegaly – The Journal of Clinical Endocrinology & Metabolism

 

Commentary on Twitter

 


Calculator | Estimating individual lifetime risk of cardiovascular events in adults with type 2 diabetes.

11 Oct, 2022 | 13:29h | UTC

Estimating individual lifetime risk of incident cardiovascular events in adults with type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2) – European Journal of Preventive Cardiology

See also: DIAL Model Calculator

 


Stay Updated in Your Specialty

No spam, just news.